nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—RET—Signaling events regulated by Ret tyrosine kinase—FRS2—nasal cavity cancer	0.0318	0.0318	CbGpPWpGaD
Sorafenib—MKNK1—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0278	0.0278	CbGpPWpGaD
Sorafenib—MAPK11—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0253	0.0253	CbGpPWpGaD
Sorafenib—BRAF—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0206	0.0206	CbGpPWpGaD
Sorafenib—BRAF—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0194	0.0194	CbGpPWpGaD
Sorafenib—RAF1—CXCR3-mediated signaling events—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Sorafenib—RAF1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0143	0.0143	CbGpPWpGaD
Sorafenib—BRAF—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0142	0.0142	CbGpPWpGaD
Sorafenib—RAF1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0134	0.0134	CbGpPWpGaD
Sorafenib—MAPK11—Signalling to ERKs—FRS2—nasal cavity cancer	0.0132	0.0132	CbGpPWpGaD
Sorafenib—BRAF—Signalling to ERKs—FRS2—nasal cavity cancer	0.0131	0.0131	CbGpPWpGaD
Sorafenib—KDR—SHP2 signaling—FRS2—nasal cavity cancer	0.0124	0.0124	CbGpPWpGaD
Sorafenib—FGFR1—Negative regulation of FGFR signaling—FRS2—nasal cavity cancer	0.0122	0.0122	CbGpPWpGaD
Sorafenib—PDGFRA—Allograft Rejection—CXCL11—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Sorafenib—MAPK11—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0115	0.0115	CbGpPWpGaD
Sorafenib—FGFR1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.0113	0.0113	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by FGFR mutants—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Sorafenib—MAP3K7—Toll-like Receptor Signaling Pathway—CXCL11—nasal cavity cancer	0.0103	0.0103	CbGpPWpGaD
Sorafenib—FGFR1—FGF signaling pathway—FRS2—nasal cavity cancer	0.00962	0.00962	CbGpPWpGaD
Sorafenib—RAF1—Signalling to ERKs—FRS2—nasal cavity cancer	0.00908	0.00908	CbGpPWpGaD
Sorafenib—RAF1—FRS2-mediated cascade—FRS2—nasal cavity cancer	0.00908	0.00908	CbGpPWpGaD
Sorafenib—MKNK1—Signaling by FGFR—FRS2—nasal cavity cancer	0.00906	0.00906	CbGpPWpGaD
Sorafenib—MAPK11—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00896	0.00896	CbGpPWpGaD
Sorafenib—MKNK1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00844	0.00844	CbGpPWpGaD
Sorafenib—PDGFRB—SHP2 signaling—FRS2—nasal cavity cancer	0.00817	0.00817	CbGpPWpGaD
Sorafenib—MAP3K7—Regulation of toll-like receptor signaling pathway—CXCL11—nasal cavity cancer	0.00808	0.00808	CbGpPWpGaD
Sorafenib—FGFR1—PI3K Cascade—FRS2—nasal cavity cancer	0.008	0.008	CbGpPWpGaD
Sorafenib—RAF1—SHP2 signaling—FRS2—nasal cavity cancer	0.00728	0.00728	CbGpPWpGaD
Sorafenib—KIT—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00699	0.00699	CbGpPWpGaD
Sorafenib—FGFR1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00669	0.00669	CbGpPWpGaD
Sorafenib—FGFR1—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00663	0.00663	CbGpPWpGaD
Sorafenib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00661	0.00661	CbGpPWpGaD
Sorafenib—FGFR1—IRS-related events—FRS2—nasal cavity cancer	0.00651	0.00651	CbGpPWpGaD
Sorafenib—FGFR1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00645	0.00645	CbGpPWpGaD
Sorafenib—KIT—PI-3K cascade—FRS2—nasal cavity cancer	0.00629	0.00629	CbGpPWpGaD
Sorafenib—FGFR1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00628	0.00628	CbGpPWpGaD
Sorafenib—FGFR1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00628	0.00628	CbGpPWpGaD
Sorafenib—KIT—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00614	0.00614	CbGpPWpGaD
Sorafenib—MAP2K5—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00612	0.00612	CbGpPWpGaD
Sorafenib—KIT—GAB1 signalosome—FRS2—nasal cavity cancer	0.0061	0.0061	CbGpPWpGaD
Sorafenib—FGFR1—PI-3K cascade—FRS2—nasal cavity cancer	0.00597	0.00597	CbGpPWpGaD
Sorafenib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Sorafenib—PDGFRA—PI-3K cascade—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Sorafenib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00596	0.00596	CbGpPWpGaD
Sorafenib—FGFR1—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00583	0.00583	CbGpPWpGaD
Sorafenib—PDGFRA—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00582	0.00582	CbGpPWpGaD
Sorafenib—FGFR1—GAB1 signalosome—FRS2—nasal cavity cancer	0.00579	0.00579	CbGpPWpGaD
Sorafenib—PDGFRA—GAB1 signalosome—FRS2—nasal cavity cancer	0.00577	0.00577	CbGpPWpGaD
Sorafenib—FGFR1—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00565	0.00565	CbGpPWpGaD
Sorafenib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Sorafenib—PDGFRB—PI-3K cascade—FRS2—nasal cavity cancer	0.00537	0.00537	CbGpPWpGaD
Sorafenib—RAF1—IRS-mediated signalling—FRS2—nasal cavity cancer	0.00536	0.00536	CbGpPWpGaD
Sorafenib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00524	0.00524	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00522	0.00522	CbGpPWpGaD
Sorafenib—RAF1—IRS-related events—FRS2—nasal cavity cancer	0.00521	0.00521	CbGpPWpGaD
Sorafenib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.0052	0.0052	CbGpPWpGaD
Sorafenib—RAF1—IRS-related events triggered by IGF1R—FRS2—nasal cavity cancer	0.00517	0.00517	CbGpPWpGaD
Sorafenib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00508	0.00508	CbGpPWpGaD
Sorafenib—RAF1—IGF1R signaling cascade—FRS2—nasal cavity cancer	0.00503	0.00503	CbGpPWpGaD
Sorafenib—RAF1—Insulin receptor signalling cascade—FRS2—nasal cavity cancer	0.00503	0.00503	CbGpPWpGaD
Sorafenib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00471	0.00471	CbGpPWpGaD
Sorafenib—BRAF—Signaling by FGFR—FRS2—nasal cavity cancer	0.00463	0.00463	CbGpPWpGaD
Sorafenib—MAP2K5—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0046	0.0046	CbGpPWpGaD
Sorafenib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00455	0.00455	CbGpPWpGaD
Sorafenib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.0045	0.0045	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00447	0.00447	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00445	0.00445	CbGpPWpGaD
Sorafenib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00443	0.00443	CbGpPWpGaD
Sorafenib—BRAF—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00431	0.00431	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00427	0.00427	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00426	0.00426	CbGpPWpGaD
Sorafenib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00423	0.00423	CbGpPWpGaD
Sorafenib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00421	0.00421	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0042	0.0042	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00419	0.00419	CbGpPWpGaD
Sorafenib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00419	0.00419	CbGpPWpGaD
Sorafenib—RAF1—Signaling by Insulin receptor—FRS2—nasal cavity cancer	0.00418	0.00418	CbGpPWpGaD
Sorafenib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.00417	0.00417	CbGpPWpGaD
Sorafenib—MAP3K7—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Sorafenib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00411	0.00411	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00402	0.00402	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00401	0.00401	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00401	0.00401	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by FGFR—FRS2—nasal cavity cancer	0.004	0.004	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00399	0.00399	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00398	0.00398	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00397	0.00397	CbGpPWpGaD
Sorafenib—FGFR1—DAP12 signaling—FRS2—nasal cavity cancer	0.00396	0.00396	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.00395	0.00395	CbGpPWpGaD
Sorafenib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.00392	0.00392	CbGpPWpGaD
Sorafenib—MAP3K7—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00392	0.00392	CbGpPWpGaD
Sorafenib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00392	0.00392	CbGpPWpGaD
Sorafenib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00392	0.00392	CbGpPWpGaD
Sorafenib—FGFR1—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0039	0.0039	CbGpPWpGaD
Sorafenib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00389	0.00389	CbGpPWpGaD
Sorafenib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00389	0.00389	CbGpPWpGaD
Sorafenib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Sorafenib—MAPK11—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00385	0.00385	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Sorafenib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00384	0.00384	CbGpPWpGaD
Sorafenib—BRAF—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00382	0.00382	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00378	0.00378	CbGpPWpGaD
Sorafenib—FGFR1—DAP12 interactions—FRS2—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Sorafenib—FGFR1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Sorafenib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00371	0.00371	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00371	0.00371	CbGpPWpGaD
Sorafenib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.00371	0.00371	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00369	0.00369	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00368	0.00368	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00366	0.00366	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00365	0.00365	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00364	0.00364	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00363	0.00363	CbGpPWpGaD
Sorafenib—MAP3K7—B Cell Activation—FRS2—nasal cavity cancer	0.00363	0.00363	CbGpPWpGaD
Sorafenib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00363	0.00363	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00361	0.00361	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00359	0.00359	CbGpPWpGaD
Sorafenib—RAF1—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00358	0.00358	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00357	0.00357	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00356	0.00356	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling by NGF—FRS2—nasal cavity cancer	0.00354	0.00354	CbGpPWpGaD
Sorafenib—RAF1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.00352	0.00352	CbGpPWpGaD
Sorafenib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.0035	0.0035	CbGpPWpGaD
Sorafenib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00347	0.00347	CbGpPWpGaD
Sorafenib—FGFR1—B Cell Activation—FRS2—nasal cavity cancer	0.00345	0.00345	CbGpPWpGaD
Sorafenib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00344	0.00344	CbGpPWpGaD
Sorafenib—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00343	0.00343	CbGpPWpGaD
Sorafenib—RAF1—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00337	0.00337	CbGpPWpGaD
Sorafenib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Sorafenib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00335	0.00335	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00332	0.00332	CbGpPWpGaD
Sorafenib—FGFR1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.0033	0.0033	CbGpPWpGaD
Sorafenib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00329	0.00329	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00329	0.00329	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00327	0.00327	CbGpPWpGaD
Sorafenib—RAF1—Downstream signal transduction—FRS2—nasal cavity cancer	0.00322	0.00322	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR—FRS2—nasal cavity cancer	0.0032	0.0032	CbGpPWpGaD
Sorafenib—RAF1—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Sorafenib—RAF1—DAP12 signaling—FRS2—nasal cavity cancer	0.00317	0.00317	CbGpPWpGaD
Sorafenib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.0031	0.0031	CbGpPWpGaD
Sorafenib—RAF1—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Sorafenib—RAF1—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Sorafenib—RAF1—DAP12 interactions—FRS2—nasal cavity cancer	0.00298	0.00298	CbGpPWpGaD
Sorafenib—MAPK11—Signaling by NGF—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Sorafenib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00296	0.00296	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR—FRS2—nasal cavity cancer	0.00295	0.00295	CbGpPWpGaD
Sorafenib—BRAF—Signaling by NGF—FRS2—nasal cavity cancer	0.00294	0.00294	CbGpPWpGaD
Sorafenib—RAF1—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00293	0.00293	CbGpPWpGaD
Sorafenib—RAF1—Signaling by PDGF—FRS2—nasal cavity cancer	0.00292	0.00292	CbGpPWpGaD
Sorafenib—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.00277	0.00277	CbGpPWpGaD
Sorafenib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.00267	0.00267	CbGpPWpGaD
Sorafenib—RAF1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Sorafenib—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00261	0.00261	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00257	0.00257	CbGpPWpGaD
Sorafenib—FGFR1—Signaling by NGF—FRS2—nasal cavity cancer	0.00254	0.00254	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—CXCL11—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00228	0.00228	CbGpPWpGaD
Sorafenib—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.00211	0.00211	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.0021	0.0021	CbGpPWpGaD
Sorafenib—RAF1—Signaling by NGF—FRS2—nasal cavity cancer	0.00203	0.00203	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00189	0.00189	CbGpPWpGaD
Sorafenib—MKNK1—Disease—FRS2—nasal cavity cancer	0.00176	0.00176	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—FRS2—nasal cavity cancer	0.00152	0.00152	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Sorafenib—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—FRS2—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.00146	0.00146	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—FRS2—nasal cavity cancer	0.00145	0.00145	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.00139	0.00139	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00134	0.00134	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.0013	0.0013	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—CXCL11—nasal cavity cancer	0.00129	0.00129	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—CXCL11—nasal cavity cancer	0.00126	0.00126	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00125	0.00125	CbGpPWpGaD
Sorafenib—CDK7—Disease—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00124	0.00124	CbGpPWpGaD
Sorafenib—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00119	0.00119	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—FRS2—nasal cavity cancer	0.00111	0.00111	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00108	0.00108	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—CXCL11—nasal cavity cancer	0.00108	0.00108	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—CXCL11—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—FRS2—nasal cavity cancer	0.000984	0.000984	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.000974	0.000974	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—CXCL11—nasal cavity cancer	0.000974	0.000974	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—CXCL11—nasal cavity cancer	0.000924	0.000924	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.000922	0.000922	CbGpPWpGaD
Sorafenib—BRAF—Disease—FRS2—nasal cavity cancer	0.0009	0.0009	CbGpPWpGaD
Sorafenib—KIT—Immune System—FRS2—nasal cavity cancer	0.000888	0.000888	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—FRS2—nasal cavity cancer	0.000888	0.000888	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—FRS2—nasal cavity cancer	0.000842	0.000842	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.00084	0.00084	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.00083	0.00083	CbGpPWpGaD
Sorafenib—KIT—Disease—FRS2—nasal cavity cancer	0.00082	0.00082	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.000792	0.000792	CbGpPWpGaD
Sorafenib—FGFR1—Disease—FRS2—nasal cavity cancer	0.000778	0.000778	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.000776	0.000776	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—FRS2—nasal cavity cancer	0.00076	0.00076	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.000757	0.000757	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00074	0.00074	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—FRS2—nasal cavity cancer	0.00074	0.00074	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.000699	0.000699	CbGpPWpGaD
Sorafenib—RAF1—Immune System—FRS2—nasal cavity cancer	0.000675	0.000675	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.000639	0.000639	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—FRS2—nasal cavity cancer	0.000636	0.000636	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—FRS2—nasal cavity cancer	0.000631	0.000631	CbGpPWpGaD
Sorafenib—RAF1—Disease—FRS2—nasal cavity cancer	0.000623	0.000623	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.000574	0.000574	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—FRS2—nasal cavity cancer	0.000574	0.000574	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—FRS2—nasal cavity cancer	0.000545	0.000545	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.000543	0.000543	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000489	0.000489	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.000467	0.000467	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—FRS2—nasal cavity cancer	0.000436	0.000436	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.000377	0.000377	CbGpPWpGaD
